Kantonsspital St.Gallen
login

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

Markus Joerger, K Matter-Walstra , Martin Früh, U Kühnel , T Szucs , B Pestalozzi & M Schwenkglenks

keywords Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.
   
citation Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
   
type journal paper/review (English)
date of publishing 4-1-2012
journal title Ann Oncol (22/3)
pages 567-574
contact Markus Joerger